Golvatinib (E7050) is primarily investigated for its potential in cancer therapy, particularly due to its ability to inhibit tyrosine kinases involved in tumor growth and angiogenesis. It targets receptors such as MET and VEGFR, which play key roles in cell proliferation, survival, and the formation of new blood vessels that support tumor development. This makes it a candidate for treating cancers where these pathways are overactive, such as certain types of gastric, liver, and kidney cancers. It has been studied in preclinical models and early-phase clinical trials to evaluate its efficacy and safety profile, especially in solid tumors with MET dysregulation. Its development highlights the ongoing effort to create targeted therapies that disrupt specific molecular mechanisms driving cancer progression.